DOI: https://doi.org/10.22141/2224-1485.3.59.2018.139904

Arterial hypertension in patients with hyperuricemia: the basis of pathogenesis, clinical significance, diagnosis, approaches to treatment

O.O. Khaniukov, Ye.D. Yehudina, O.S. Kalashnykova

Abstract


The leading cause of death of hyperuricemic patients are cardiovascular diseases. The article presents a review of the literature and analysis of the mechanisms of correlation between arterial hypertension and hyperuricemia. We made the conclusion that careful blood pressure control, monitoring of target organ damage can be used as the basis for the prevention of cardiovascular diseases and the development of cardiovascular emergencies in patients with hyperuricemia. When carrying out antihypertensive therapy in such patients, it is necessary to take into account the effect of drugs on lipid and carbohydrate metabolism, the level of uric acid. The therapy should be sufficient and have high antihypertensive efficacy.


Keywords


hyperuricemia; cardiovascular diseases; arterial hypertension; treatment; review

References


Maiuolo J., Oppedisano F., Gratteri S., Muscoli C., Mollace V. Regulation of uric acid metabolism and excretion. Int J Cardiol. 2016; 213: 8–14. doi: 10.1016/j.ijcard.2015.08.109, PMID:26316329.

Dalbeth N., Merriman T., Stamp L. Gout. The Lancet. 2016; 388(10055): 2039–2052. doi: 10.1016/s0140­6736(16)00346­9 PMID:27112094.

Norvik J.V., Storhaug H.M., Ytrehus K. et al. Overweight modifies the longitudinal association between uric acid and some components of the metabolic syndrome: The Tromsø Study. BMC Cardiovasc Disord. 2016; 16: 85–98. doi: 10.1186/s12872­016­0265­8, PMID:: 27165776.

Lin K.C., Lin H.Y., Chou P. The interaction between uric acid level and other risk factors on the development of gout among asymptomatic hyperuricemic men in a prospective study. J Rheumatol. 2000; 27(6): 1501–1505, PMID: 10852278.

Abeles A.M. Hyperuricemia, gout, and cardiovascular disease: an update. Curr Rheumatol Rep. 2015; 17(3): 13. doi: 10.1007//s11926­015­0495­2, PMID: 25740704.

Billiet L., Doaty S., Katz J.D., Velasquez M.T. Review of Hyperuricemia as New Marker for Metabolic Syndrome ISRN Rheumatol.2014: 1-7. doi.org/10.1155/2014/852954

Enomoto A., Endou H. Roles of organic anion transporters (OATs) and a urate transporter (URAT1) in the pathophysiology of human disease. Clin Exp Nephrol. 2005; 9(3): 195–205. doi: 10.1007//s10157­005­0368­5, PMID: 16189627.

Feig D.I., Kang D.H., Johnson R.J. Uric acid and cardiovascular risk. N Engl J Med. 2008; 359(17): 1811–1821. doi: 10.1056/NEJ­ Mra0800885, PMID: 18946066.

Perez­Ruiz F., Becker M.A. Inflammation: a possible mechanism for a causative role of hyperuricemia/gout in cardiovascular disease. Curr Med Res Opin. 2015; 31(2): 9–14. doi: 10.1185/03007995.2015.1087980, PMID: 26414731.

Glantzounis G.K., Tsimoyiannis E.C., Kappas A.M., Galaris D.A. Uric acid and oxidative stress. Curr Pharm Des. 2005; 11(32): 4145–4151. PMID: 16375736.

Kucharz E.J. Chronic inflammation­enhanced atherosclerosis: can we consider it as a new clinical syndrome? Med Hypotheses. 2012; 78(3): 396–397. doi: 10.1016/j.mehy.2011.11.020, PMID: 22182962.

Smith E., Hoy D., Cross M. et al. The global burden of gout: estimates from the Global Burden of Disease 2010 study. Ann Rheum Dis. 2014;73(8):1470-6. doi: 10.1136/annrheumdis-2013-204647. PMID:24590182.

Roddy E., Choi H.K. Epidemiology of gout. Rheum Dis Clin North Am. 2014; 40(2): 155–175. doi: 10.1016/j.rdc.2014.01.001, PMID: 24703341.

Qiu L., Cheng Xq., Wu J. et al. Prevalence of hyperuricemia and its related risk factors in healthy adults from Northern and Northeastern Chinese provinces. BMC Public Health. 2013; 13: 664. doi: 10.1186/1471­2458­13­664, PMID: 23866159.

Perlstein T.S., Gumieniak O., Williams G.H. et al. Uric acid and the development of hypertension: the normative aging study. Hypertension. 2006; 48(6): 1031–1036. doi: 10.1161/01. HYP.0000248752.08807.4c, PMID:17060508.

Syamala S., Li J., Shankar A. Association between serum uric acid and prehypertension among US adults. J Hypertens. 2007; 25(8): 1583–1589. doi: 10.1097/HJH.0b013e32813aeb6c, indexed in Pubmed: 17620953.

Kuwabara M. Hyperuricemia, Cardiovascular Disease, and Hypertension Pulse (Basel). 2016 Apr; 3(3-4): 242–252. doi: 10.1159/000443769, PMID: 27195245.

Ruggiero C., Cherubini A., Lauretani F et al. Uric acid and dementia in community­dwelling older persons. Dement Geriatr Cogn Disord. 2009; 27(4): 382–389. doi: 10.1159/000210040, PMID: 19339776.

Sautin Y.Y., Johnson R.J. Uric acid: the oxidant­antioxidant paradox. Nucleosides Nucleotides Nucleic Acids. 2008; 27(6): 608–619. doi: 10.1080/15257770802138558, PMID: 18600514.

Ioachimescu A.G., Brennan D.M., Hoar B.M., Hazen S.L., Hoogwerf B.J. Serum uric acid is an independent predictor of all­cause mortality in patients at high risk of cardiovascular disease: a preventive cardiology information system (PreCIS) database cohort study. Arthritis Rheum. 2008; 58(2): 623–630. doi: 10.1002/art.23121, PMID: 18240236.

Grygiel-Górniak B., Mosor M., Marcinkowska J., Przysławski J., Nowak J. Uric acid and obesity-related phenotypes in postmenopausal women Mol Cell Biochem. 2018; 443(1): 111–119.  doi:  10.1007/s11010-017-3215-6, PMID:29075989

Puddu P., Puddu G.M., Cravero E., Vizioli L., Muscari A. Relationships among hyperuricemia, endothelial dysfunction and cardiovascular disease: molecular mechanisms and clinical implications. J Cardiol. 2012; 59(3): 235–242. doi: 10.1016/j.jjcc.2012.01.013, PMID: 22398104.

Mahomed F.A. On chronic Bright's disease, and its essential symptoms. Lancet 1879;1:399–401.

Haig A. On uric acid and arterial hypertension. BMJ 1889;1:288–91.

Huchard H. Allgemeine Betrachtungen ü ber die Arteriosklerose. Klin Med Berlin 1909;5:1318–21.

Mikkelsen W.M., Dodge H.J., Valkenburg H. The distribution of serum uric acid values in a population unselected as to gout or hyper- uricemia. Tecumseh, Michigan 1959–1960. Am J Med 1965;39:242–51.

Wallace S.L. Gout and hypertension. Arthr Rheum 1975;18:721–3.

Alper A.B. Jr., Chen W., Yau L.. Srinivasan S.R., Berenson G.S., Hamm L.L. Childhood uric acid predicts adult blood pressure: the Bogalusa Heart Study. Hypertension 2005;45:34–8. doi:10.1161/01.HYP.0000150783.79172.bb, PMID:15569853

Lee J.E., Kim Y.G., Choi Y.H., Huh W., Kim D.J., Oh H.Y. Serum uric acid is associated with microalbuminuria in prehypertension. Hypertension. 2006; 47(5): 962–967. doi: 10.1161/01.HYP.0000210550.97398.c2, PMID: 16520402.

Nagahama K., Inoue T., Iseki K., Touma T., Kinjo K., Ohya Y., Takishita S. Hyperuricemia as a predictor of hypertension in a screened cohort in Okinawa, Japan. Hypertens Res. 2004; 27(11):835-41. PMID:15824465.

Taniguchi Y., Hayashi T., Tsumura K., Endo G., Fujii S., Okada K. Serum uric acid and the risk for hypertension and Type 2 diabetes in Japanese men: The Osaka Health Survey. J Hypertens 2001;19(7):1209–15. PMID:11446710.

Grayson P.,   Kim S. Y., LaValley M., Cho Hyon K.i Hyperuricemia and Incident Hypertension: A Systematic Review and Meta-AnalysisArthritis Care Res (Hoboken). 2011 Jan; 63(1): 102–110. doi:  10.1002/acr.20344, PMID:20824805

Sundström J., Sullivan L., D'Agostino R.B. et al. Relations of serum uric acid to longitudinal blood pressure tracking and hypertension incidence. Hypertension 2005;45(1):28–33. doi:10.1161/01.HYP.0000150784.92944.9a, PMID:15569852

Ndrepepa G., Braun S., Haase H.U. [et al.] Prognostic value of uric acid in patients with acute coronary syndromes. Am J Cardiol. 2012; 109(9): 1260–1265. doi: 10.1016/j.amjcard.2011.12.018, PMID 22325088.

Fang J., Alderman M. Serum uric acid and cardiovascular mortality: The NHANES I epidemiologic follow-up study, 1971–1992. National Health and Nutrition Examination Survey. JAMA 2000;238:2404–10. PMID:10815083

Verdecchia P., Schillaci G., Reboldi G., Santeusanio F., Porcellati C., Brunetti P. Relation between serum uric acid and risk of cardiovascular disease in essential hypertension. The PIUMA study. Hypertension 2000;36:1072–8. PMID:11116127.

Bhole V., de Vera M., Rahman M.M., Krishnan E., Choi H. Epidemiology of gout in women: fifty-two–year followup of a prospective cohort. Arthritis Rheum 2010;62:1069–769 doi:10.1002/art.27338, PMID:20131266.

Pillinger M.H., Goldfarb D.S., Keenan R.T. Gout and its comorbidities. Bull NYU Hosp Jt Dis 2010; 68: 199–203. PMID: 20969552.

Li Q., Zhou Y., Dong K. et al. The Association between Serum Uric Acid Levels and the Prevalence of Vulnerable Atherosclerotic Carotid Plaque: A Cross-sectional Study Sci Rep. 2015; 5: 1003. doi:  10.1038/srep10003, PMID:25961501.

Gibson T.J. Hypertension, its treatment, hyperuricemia and gout. Curr Opin Rheumatol. 2013 Mar;25(2):217-22. doi: 10.1097/BOR.0b013e32835cedd4. PMID:23370375.

Krishnan E., Baker J.F., Furst D.E. et al. Gout and risk of acute myocardial infarction. Arthr Rheum. 2006; 54(8): 2688–96.

Choi H.K., Mount D.B., Reginato A.M. American Pathogenesis of gout. Ann Intern Med. 2005; 143(7):499-516. PMID:16204163.

Johnson R.J., Kang D.-N., Feig D. et al. Is there a pathogenetic role for uric acid in hypertension and cardiovascular and renal disease? Hypertension 2003;41:1183–90. doi:10.1161/01.HYP.0000069700.62727.C5, PMID:12707287

Johnson R.J., Rodriguez-Iturbe B., Kang D.H., Feig D.I., Herrera-Acosta J. A unifying pathway for essential hypertension. Am J Hypertens 2005;18:431–40. doi:10.1016/j.amjhyper.2004.08.035, PMID:15797666.

Nakagawa Т., Mazzali M., Kang D-H. et al. Hyperuricemia causes glomerular hypertrophy in the rat. Am J Nephrol 2003;23:2–7. doi:10.1159/000066303, PMID:12373074.

Milionis H., Kakafika A. Effects of statin treatment on uric acid homeostasis in patients with primary hyperlipidemia. Am. Heart. J.2004;148(4):635–640. doi:10.1016/j.ahj.2004.04.005 PMID:15459594.

Mazzali M., Hughes J., Kim Y.G. et al. Elevated uric acid increases blood pressure in the rat by a novel crystal-independent mechanism. Hypertension 2001;38(5);1101–6. PMID:11711505

Mazzali M, Kanellis J, Han L. et al. Hyperuricemia induces a primary renal arteriolopathy in rats by a blood pressure-independent mechanism. Am J Physiol Renal Physiol 2002;282 (6):991–7. doi:10.1152/ajprenal.00283.2001, PMID:11997315.

Puig J.G., Ruilope L.M. Uric acid as a cardiovascular risk factor in arterial hypertension. J Hypertens 1999;17:869–72. PMID:10419058.

Leyva F., Anker S., Swan J.W. et al. Serum Uric Acid as an index of impaired oxidative metabolism in chronic heart failure. Eur Heart J 1997;8:858–65.

Johnson R.J., Herrera-Acosta J., Schreiner G.F., Rodriguez-Iturbe B. Subtle acquired renal injury as a mechanism of salt-sensitive hypertension. N Engl J Med 2002;346:913–23. doi:10.1056/NEJMra011078, PMID:11907292.

Berni A., Boddi M., Fattori E.B. et al.  Serum uric acid levels and renal damage in hyperuricemic hypertensive patients treated with renin-angiotensin system blockers. Am J Hypertens. 2010;23(6):675-80. doi: 10.1038/ajh.2010.33. PMID:20203626

Thottam G.E., Krasnokutsky S., Pillinger M.H. Gout and Metabolic Syndrome: a Tangled Web. Curr Rheumatol Rep. 2017;19(10):60. doi: 10.1007/s11926-017-0688-y.

Simonenko V.B., Medvedev I.N., Tolmachev V.V. Pathogenetic aspects of arterial hypertension in metabolic syndrome Klin Med (Mosk). 2011;89(1):49-51. PMID:21516767.

El-Atat F.A. Sameer S.N., Samy I., Sowers J.R. The Relationship between Hyperinsulinemia, Hypertension and Progressive Renal Disease. JASN 2004;15(11): 2816-2827. doi:10.1097/01.ASN.0000133698.80390.37.

Tarray R., Saleem S., Afroze D. et al. Role of insulin resistance in essential hypertension. Cardiovascular Endocrinology & Metabolism. 2014; 3(4): P. 129–133. doi:10.1097/XCE.0000000000000032.

Duvnjak L., Tomislav B., Željko M. Hypertension and the metabolic syndrome. Diabetologia Croatica 2008;37:4.

Giridhara R.,  Murthy G.V.S.,  Ana Yamuna et al. Association of obesity with hypertension and type 2 diabetes mellitus in India: A meta-analysis of observational studies World J Diabetes 2018; 9(1): 40–52. doi: 10.4239/wjd.v9.i1.40

Thorp A.A., Schlaich M.P. Relevance of Sympathetic Nervous System Activation in Obesity and Metabolic Syndrome. Journal of Diabetes Research 2015; 11. doi.org/10.1155/2015/341583

Brent M.E. Insulin resistance and the sympathetic nervous system. Current Hypertension Reports 2003; 5(3):247–254.

Wang Q,  Liu Y.,  Fu Q. et al. Inhibiting Insulin-Mediated β2-Adrenergic Receptor Activation Prevents Diabetes-Associated Dysfunction // Cardiac Circulation. 2017;135:73-88. doi.org/10.1161/CIRCULATIONAHA.116.022281 

Rabmouni K., Correia M.L.G., Hayens W.G. el al. Obesety-associated hypertension. New insights into mechanisms. Hypertension 2005;45:9–14.

Tang L., Kubota M., Nagai A. et al. Hyperuricemia in obese children and adolescents: the relationship with metabolic syndrome. Pediatr Rep. 2010; 2(1): e12. doi:  10.4081/pr.2010.e12.

Mancia G., de Backer G., Dominiczak A. et al. Guidelines for the Management of Arterial Hypertension: The Task Force for the Management of Arterial Hypertension of the European Society of Hypertension (ESC). J Hypertens 2007;25(6):1105–87.

Jiang Y., Berry D.C., Tang W., Graff J.M. Independent stem cell lineages regulate adipose organogenesis and adipose homeostasis. Cell Rep. 2014;9(3):1007-22. doi: 10.1016/j.celrep.2014.09.049.

Stern J.H.,  Rutkowski J.M., Scherer P.E. Adiponectin, Leptin, and Fatty Acids in the Maintenance of Metabolic Homeostasis Through Adipose Tissue Crosstalk. Cell Metab. 2016; 23(5): 770–784. doi:  10.1016/j.cmet.2016.04.011

Belfort R., Mandarino L., Kashyap S. et al. Dose-Response Effect of Elevated Plasma Free Fatty Acid on Insulin Signaling. Diabetes 2005; 54(6): 1640-1648. doi.org/10.2337/diabetes.54.6.1640

Chu N.F., Wang D.J., Shieh S.M., Rimm E.B. Plasma leptin concentrations and obesity in relation to insulin resistance syndrome components among school children in Taiwan--The Taipei Children Heart Study. Int J Obes Relat Metab Disord. 2000;24(10):1265-71.

Filer J.S. Leptin resistance and obesity. Presented at the 60th Scientific Sessions of the american diabetes association, 2000, San- Antonio, Texas

Yamagishi S.I., Edelstein D., Du X.L. et al. Leptin induces mitochondrial superoxide production and monocyte chemoattractant protein-1 expression in aortic endothelial cells by increasing fatty acid oxidation via protein kinase A. J Biol Chem 2001;276(27):25096–100.

Quehenberger P., Exner M., Sunder R. et al. Leptin induces endothelin-1 in endothelial cells in vitro. Circ Res 2002;90:711–8.

Shin H.J., Oh J., Kang S.M. et al. Leptin induces hypertrophy via p38 mitogen-activated protein kinase in rat vascular smooth muscle cells. Biochem. Biophys Res Commun 2005;329:18–24.

Parhami F., Tintut Y., Ballard A. et al. Leptin enhances the calcification of vascular cells: artery wall as a target of leptin. Circ Res 2001;88:954–60.

Efstratiadis G., Nikolaidou C. Leptin as a cardiovascular risk factor. Hippocratia 2007; 11(4): 163–170. PMID:19582187.

Söderberg SStegmayr BAhlbeck-Glader C. High leptin levels are associated with stroke. Cerebrovasc Dis. 2003;15(1-2):63-9. PMID:12499713.

Mathew J., Sleight P., Lonn E. et al. Reduction of cardiovascular risk by regression of elecrocardiographic markers of left ventricular hypertrophy by the angiotensin enzyme inhibitor, ramipril / Circulation 2001;104:1615–21.

Cuspidi C., Rescaldani M., Sala C., Grassi G. Left-ventricular hypertrophy and obesity: a systematic review and meta-analysis of echocardiographic studies. J Hypertens. 2014;32(1):16-25. doi: 10.1097/HJH.0b013e328364fb58.

Kuo C.F., Yu K.H., Luo S.F. et al. Role of uric acid in the link between arterial stiffness and cardiac hypertrophy: a cross- sectional study. Rheumatology 2010;49(6):1189–96.

Struijker Boudier H.A.J. Hypertension and the microcirculation. In: Kaplan N., ed. Hypertension, microcirculation and end organ damage. London. Lippincott Williams & Wilkins 2002;49–55.

Chamorro A., Obach V., Cervera A. et al. Prognostic Significance of Uric Acid Serum Concentration in Patients With Acute Ischemic Stroke. Stroke 2002; 33(4): 1048–1052. doi: 10.1161//hs0402.105927.

Amaro S, Soy D, Obach V. et al. A Pilot Study of Dual Treatment With Recombinant Tissue Plasminogen Activator and Uric Acid in Acute Ischemic Stroke. Stroke 2007; 38(7): 2173–2175. doi: 10.1161/strokeaha.106.480699.

Duan W., Ladenheim B., Cutler R.G. et al. Dietary folate deficiency and elevated homocysteine levels endanger dopaminergic neurons in models of Parkinson’s disease. J Neurochem. 2002; 80(1): 101–110. PMID: 11796748.

Imaram W., Gersch C., Kim K.M. et al. Radicals in the reaction between peroxynitrite and uric acid identified by electron spin resonance spectroscopy and liquid chromatography mass spectro­ metry. Free Radic Biol Med. 2010; 49(2): 275–281. doi: 10.1016/j. freeradbiomed.2010.04.010, PMID: 20406679.

Ríos María T., Domínguez-Sardiña M., Ayala Diana E. et al. Prevalence and Clinical Characteristics of Isolated-Office and True Resistant Hypertension Determined by Ambulatory Blood Pressure Monitoring. The Journal of Biological and Medical Rhythm Research 2013; 30(1-2): 207-220. doi.org/10.3109/07420528.2012.701135.

Höcht C. Blood Pressure Variability: Prognostic Value and Therapeutic Implications. ISRN Hypertension 2013; 2013: 16. doi.org/10.5402/2013/398485.

Nagano M., Takahashi M., N. Miyai et al. Association of serum uric acid with subsequent arterial stiffness and renal function in normotensive subjects. Hypertens Res. 2017;40(6):620-624. doi: 10.1038/hr.2017.10.

Torbas O.O., Rekovets O.L., Sirenko Yu.M. Influence of hyperuricemia on arterial stiffness in patients with arterial hypertension. Arterialnaya hypertensia 2017; 4 (54):P.58-65

Armstrong A.C. LV mass assessed by echocardiography and CMR, cardiovascular outcomes, and medical practice. J Am Coll Cardiol Img 2012;5:837–438.

Greenland P., Alpert J.S., Beller G.A. et al. 2010 ACCF/AHA guideline for assessment of cardiovascular risk in asymptomatic adults: a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines. J Am Coll Cardiol. 2010;56:e50–103.

Okwuosa T.M., Soliman E.Z., Lopez F. et al. Left ventricular hypertrophy and cardiovascular disease risk prediction and reclassification in blacks and whites: the Atherosclerosis Risk in Communities Study. Am Heart J. 2015; 169:155–161.

Mara A., Janet W., Alan N.  et al. Diuretic Use, Increased Serum Urate and the Risk of Incident Gout in a Population-based Study of Hypertensive Adults: the Atherosclerosis Risk in the Communities Cohort Arthritis Rheum. 2012 Jan; 64(1): 121–129. doi:  10.1002/art.33315

Reyes A.J. Cardiovascular drugs and serum uric acid. Cardiovasc Drugs Ther. 2003; 17(5-6):397-414.

Hunter D.J., York M., Chaisson C.E. et al. Recent diuretic use and the risk of recurrent gout attacks: the online case-crossover gout study. J Rheumatol. 2006; 33(7):1341-5.

Taniguchi Y., Hayashi T., Tsumura K. et al. Serum uric acid and the risk for hyperten- sion and Type 2 diabetes in Japanese men: The Osaka Health Survey. J Hypertens 2001;19(7):1209–15.

El-Sheikh A.A.K., van den Heuvel J.J.M.W., Koenderink J.B., Russel F.G.M. Effect of hypouricaemic and hyperuricaemic drugs on the renal urate efflux transporter, multidrug resistance protein 4. Br J Pharmacol. 2008; 155(7): 1066–1075.

Ruilope L.M., Kirwan B.A., de Brouwer S. et al. Uric acid and other renal function parameters in patients with stable angina pectoris participating in the ACTION trial: impact of nifedipine GITS (gastro-intestinal therapeutic system) and relation to outcome. J Hypertens. 2007; 25(8):1711-8.

Hoieggen A., Alderman M.H., Kjeldsen S.E. et al. The impact of serum uric acid on cardiovascular outcomes in the LIFE study. Kidney Int 2004;65:1041-9.

Nishida Y.,  Takahashi Y.,  Tezuka K. et al. Comparative Effect of Calcium Channel Blockers on Glomerular Function in Hypertensive Patients with Diabetes Mellitus. Drugs R D. 2017; 17(3): 403–412.  doi:  10.1007/s40268-017-0191-y.

Chanard J., Toupance O., Lavaud S et al. Amlodipine reduces cyclosporin-induced hyperuricaemia in hypertensive renal transplant recipients. Nephrol Dial Transplant. 2003;18(10):2147-53.

Wahda B.A.Y., Yasir Y.T.A. Serum uric acid level and renal function tests in hypertensive patients treated by captopril. Iraqi Journal of Pharmacy 2013;13(2): 1-10. 

Li H., Qin X., Xie D. Et al. Effects of combined enalapril and folic acid therapy on the serum uric acid levels in hypertensive patients: a multicenter, randomized, double-blind, parallel-controlled clinical trial. Intern Med. 2015;54(1):17-24. doi: 10.2169/internalmedicine.54.2931.

Myers M.G., Asmar R., Leenen F.H., Safar M. Fixed low-dose combination therapy in hypertension – a dose response study of perindopril and indapamide // J Hypertens 2000;18(3):317–25.

Dahlof B., Devereux R.B., Kjeldsen S.E. et al. Cardiovascular morbidity and mortality in the losartan intervention for endpoint reduction in hypertension study (LIFE): a randomised trial against atenolol. Lancet 2002;359:995–1003.

Shahinfar S., Simpson R.L., Carides A.D. et al. Safety of losartan in hypertensive patients with thiazide-induced hyperuricemia. Kidney Int 1999; 56: 1879–85.

González-Ortiz M., Mora-Martínez J.M., Martínez-Abundis E., Balcázar-Muñoz B.R. Effect of valsartan on renal handling of uric acid in healthy subjects. J Nephrol. 2000; 13(2):126-8.

Manolis A.J., Grossman E., Jelakovic B. et al. Effects of losartan and candesartan monotherapy and losartan/hydrochlorothiazide combination therapy in patients with mild to moderate hypertension. Losartan Trial Investigators. Clin Ther. 2000; 22(10):1186-203.

Burgess E.D., Buckley S. Acute natriuretic effect of telmisartan in hypertensive patients. Am J Hypertens 2000;13:183A.

Würzner G., Gerster J.C., Chiolero A. et al. Comparative effects of losartan and irbesartan on serum uric acid in hypertensive patients with hyperuricaemia and gout. J Hypertens. 2001; 19(10):1855-60.

Rubio-Guerra A.F., Ana K.G., Cesar I. E., Juan A.S., Montserrat B.D. Effect of losartan combined with amlodipine or with a thiazide on uric acid levels in hypertensive patients. Ther Adv Cardiovasc Dis 2017;11(2): 57–62. doi: 10.1177/ 1753944716678538.

Dincer E., Dincer A., Levinson D. Asymptomatic hyperuricemia:To treat or not to treat. Cleveland Clinic Journal of Medicine 2002; 69(8): 594-597. DOI:10.3949/ccjm.69.8.594

Kelkar A., Kuo A., Frishman W.H. Allopurinol as a cardiovascular drug. Cardiol Rev. 2011; 19(6): 265–271. doi: 10.1097//CRD.0b013e318229a908, PMID: 21983313.

Stamp L.K., Taylor W.J., Jones P.B. et al. Starting dose is a risk factor for allopurinol hypersensitivity syndrome: a proposed safe starting dose of allopurinol. Arthritis Rheum. 2012; 64(8): 2529–2536. doi: 10.1002/art.34488, PMID: 22488501.

Seth R., Kydd A., Buchbinder R. et al. Allopurinol for chronic gout. Cochrane Database of Systematic Reviews. 2014. doi: 10.1002/14651858.cd006077.pub3, PMID: 25314636.

Luk A.J., Levin G.P., Moore E.E. et al. Allopurinol and mortality in hyperuricaemic patients. Rheumatology (Oxford). 2009; 48(7): 804–806. doi: 10.1093/rheumatology/kep069, PMID: 19447769.

Dubreuil M., Zhu Y., Zhang Y. et al. Allopurinol initiation and all­ cause mortality in the general population. Ann Rheum Dis. 2015; 74(7): 1368–1372. doi: 10.1136/annrheumdis­2014­205269, indexed in Pubmed: 24665118.

Deng G., Qiu Z., Li D. et al. Effects of Allopurinol on Arterial Stiffness: A Meta­Analysis of Randomized Controlled Trials. Med Sci Monit. 2016; 22: 1389–1397, PMID: 27110924.

Bruce S.P. Febuxostat: a selective xanthine oxidase inhibitor for the treatment of hyperuricemia and gout. Ann Pharmacother. 2006; 40(12): 2187–2194. doi: 10.1345/aph.1H121, PMID: 17132810].




Copyright (c) 2018 HYPERTENSION

Creative Commons License
This work is licensed under a Creative Commons Attribution 4.0 International License.

 

© Publishing House Zaslavsky, 1997-2018

 

   Seo анализ сайта